Lashonda Spencer
Pediatric Infectious Diseases · Los Angeles, CANPI 1902904824
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,570 of the $122,659 with a category attached, or 66.5%. Gilead accounts for 91.2% of it on its own, with 7 other manufacturers making up the rest. Among pediatric infectious diseases clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $601.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$112K
- Janssen Scientific Affairs, LLC$7K
- Theratechnologies Inc.$3K
- Viiv Healthcare Company$1K
- Johnson & Johnson$239
- Merck$57
- plus $73 from 2 others
Across 34 payments — averaging $3737.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$72K
- Viiv Healthcare Company$55K
What the payments were for
- Consulting fees$18,81015%
- Speaking & faculty fees$81,57067%
- Grants$6,5005%
- Travel & lodging$9,5438%
- Food & beverage$6,0955%
- Education$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 163 | $111,913 |
| Janssen Scientific Affairs, LLC | 3 | $6,500 |
| Theratechnologies Inc. | 1 | $2,500 |
| Viiv Healthcare Company | 24 | $1,378 |
| Johnson & Johnson(2 entities) | 9 | $239 |
| Merck | 2 | $57 |
| Janssen Products, LP | 1 | $55 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$122,659 in reported general payments places this provider in the 95th percentile of 83 pediatric infectious diseases providers in California.
See all pediatric infectious diseases providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 86 | $325,298 |
| JulucaDolutegravir/Rilpivirine | 46 | $160,105 |
| TivicayDolutegravir Sodium | 48 | $119,266 |
| RukobiaFostemsavir Tromethamine | 11 | $112,989 |
| DescovyEmtricitabine/Tenofov Alafenam | 51 | $108,983 |
| PrezcobixDarunavir/Cobicistat | 30 | $74,848 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 16 | $62,294 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $45,898 |
| OzempicSemaglutide | 21 | $16,962 |
| EliquisApixaban | 16 | $9,668 |
| JardianceEmpagliflozin | 17 | $8,946 |
| EntrestoSacubitril/Valsartan | 13 | $8,899 |
| PremarinEstrogens, Conjugated | 11 | $1,941 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $955 |
| Gemfibrozil | 15 | $351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $111,913 | $480,179149 claims |
| Viiv Healthcare CompanyJuluca, Tivicay, Rukobia, Triumeq | $1,378 | $454,654121 claims |
| Johnson & JohnsonPrezcobix | $239 | $74,84830 claims |
| PfizerEliquis, Premarin | $18 | $11,60927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 83 pediatric infectious diseases providers in California.
Other pediatric infectious diseases in Los Angeles
- Jaime DevilleLos Angeles$16K
- Michael NeelyLos Angeles$14K
- Annabelle de St MauriceLos Angeles$5K
- James CherryLos Angeles$3K
- Mikhaela CieloLos Angeles$336
- Mark SalzmanLos Angeles$186
- Paul KrogstadLos Angeles$154
- Jennifer RatheLos Angeles$125
- Leila PoschLos Angeles$124
- Grace AldrovandiLos Angeles$121
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.